The Analyst Landscape: 4 Takes On iRhythm Technologies


In the latest quarter, 4 analysts provided ratings for iRhythm Technologies IRTC, showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 1 0 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 2 1 0 0 0

Analysts have recently evaluated iRhythm Technologies and provided 12-month price targets. The average target is $135.25, accompanied by a high estimate of $138.00 and a low estimate of $133.00. Marking an increase of 0.93%, the current average surpasses the previous average price target of $134.00.

Exploring Analyst Ratings: An In-Depth Overview

An in-depth analysis of recent analyst actions unveils how financial experts perceive iRhythm Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
David Saxon Needham Raises Buy $138.00 $137.00
Allen Gong JP Morgan Lowers Overweight $133.00 $142.00
William Plovanic Canaccord Genuity Raises Buy $133.00 $121.00
David Saxon Needham Raises Buy $137.00 $136.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to iRhythm Technologies. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of iRhythm Technologies compared to the broader market.
  • Price Targets: Delving into movements, analysts provide estimates for the future value of iRhythm Technologies's stock. This analysis reveals shifts in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of iRhythm Technologies's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on iRhythm Technologies analyst ratings.

Discovering iRhythm Technologies: A Closer Look

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

iRhythm Technologies's Financial Performance

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Positive Revenue Trend: Examining iRhythm Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 17.67% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: iRhythm Technologies's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -29.2%, the company may face hurdles in effective cost management.

Return on Equity (ROE): iRhythm Technologies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -18.0%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): iRhythm Technologies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -8.87%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: iRhythm Technologies's debt-to-equity ratio is below the industry average at 0.62, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!